SequelSEC

Instil Bio, Inc. TIL

Biological Products, (No Diagnostic Substances) · CIK 0001789769 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2021-12-31
Operating income
-$155.56M
Fiscal year ended 2021-12-31
Free cash flow
-$179.97M
Fiscal year ended 2021-12-31

Instil Bio, Inc. (TIL) reported revenue of $0 and net income of -$156.79M for the fiscal year ended 2021-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Instil Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Instil Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$155.56M
Net income-$156.79M
Research & development$107.25M
Weighted-average diluted sharesUnavailable
Pretax income-$156.76M
Income tax expense$39.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$48.31M
Selling & marketingUnavailable

Balance

Instil Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Cash & equivalents$37.59M
Total assets$609.98M
Current assets$464.02M
Total liabilities$54.78M
Current liabilities$41.36M
Total equity incl. NCI$555.20M
Temporary (mezzanine) equity$0
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$5.72M
Long-term debtUnavailable
Accounts payable$5.57M

Cash flow

Instil Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Operating cash flow-$122.14M
Capital expenditures$57.83M
Investing cash flow-$474.40M
Financing cash flow$393.16M
Net change in cashUnavailable
Stock-based compensation$26.20M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.75M

Derived

Instil Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Free cash flow-$179.97M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio11.22x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TIL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.